Activation or overexpression of the PGC-1α could be used to compensate for neuronal mitochondrial loss and suggest that therapeutic agents activating PGC-1α would be valuable for treating neurodegenerative diseases in which mitochondrial dysfunction and oxidative damage play an important pathogenic role [74]. Here, PPARGC1A is linked to neurodegenerative disease.